Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 8/2007

01.08.2007 | Original Article

[F-18]-Fluoro-2-deoxy-d-glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model

verfasst von: Coralie Chaise, Emmanuel Itti, Yolande Petegnief, Evelyne Wirquin, Christiane Copie-Bergman, Jean-Pierre Farcet, Marie-Hélène Delfau-Larue, Michel Meignan, Jean-Noël Talbot, Valérie Molinier-Frenkel

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 8/2007

Einloggen, um Zugang zu erhalten

Abstract

[F-18]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) is a non-invasive imaging technique which has recently been validated for the assessment of therapy response in patients with aggressive non-Hodgkin’s lymphoma. Our objective was to determine its value for the evaluation of immunotherapy efficacy in immunocompetent Balb/c mice injected with the A20 syngeneic B lymphoma cell line. The high level of in vitro FDG uptake by A20 cells validated the model for further imaging studies. When injected intravenously, the tumour developed as nodular lesions mostly in liver and spleen, thus mimicking the natural course of an aggressive human lymphoma. FDG-PET provided three-dimensionnal images of tumour extension including non-palpable lesions, in good correlation with ex vivo macroscopic examination. When mice were pre-immunized with an A20 cell lysate in adjuvant before tumour challenge, their significantly longer survival, compared to control mice, were associated with a lower incidence of lymphoma visualized by PET at different time points. Estimation of tumour growth and metabolism using the calculated tumour volumes and maximum standardized uptake values, respectively, also demonstrated delayed lymphoma development and lower activity in the vaccinated mice. Thus, FDG-PET is a sensitive tool relevant for early detection and follow-up of internal tumours, allowing discrimination between treated and non-treated small animal cohorts without invasive intervention.
Literatur
1.
Zurück zum Zitat Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 105:1376–1381CrossRef Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M (2005) [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 105:1376–1381CrossRef
2.
Zurück zum Zitat Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 13:1356–1363PubMedCrossRef Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 13:1356–1363PubMedCrossRef
3.
Zurück zum Zitat Juweid ME, Cheson BD (2005) Role of positron emission tomography in lymphoma. J Clin Oncol 23:4577–4580PubMedCrossRef Juweid ME, Cheson BD (2005) Role of positron emission tomography in lymphoma. J Clin Oncol 23:4577–4580PubMedCrossRef
4.
Zurück zum Zitat Czernin J, Weber WA, Herschman HR (2006) Molecular imaging in the development of cancer therapeutics. Annu Rev Med 57:99–118PubMedCrossRef Czernin J, Weber WA, Herschman HR (2006) Molecular imaging in the development of cancer therapeutics. Annu Rev Med 57:99–118PubMedCrossRef
5.
Zurück zum Zitat Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, Yamada Y, Inoue K, Manabe T, Imura H (1990) Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 170:223–230PubMedCrossRef Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, Yamada Y, Inoue K, Manabe T, Imura H (1990) Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 170:223–230PubMedCrossRef
6.
Zurück zum Zitat Ido T, Wan CN, Casella JS et al (1978) Labeled 2-deoxy-d-glucose analogs: 18F labeled 2-deoxy-2-fluoro-d-glucose, 2-deoxy-2-fluoro-d-mannose and 14C-2-deoxy-2-fluoro-d-glucose. J Labeled Comp Radiopharm 14:175–183CrossRef Ido T, Wan CN, Casella JS et al (1978) Labeled 2-deoxy-d-glucose analogs: 18F labeled 2-deoxy-2-fluoro-d-glucose, 2-deoxy-2-fluoro-d-mannose and 14C-2-deoxy-2-fluoro-d-glucose. J Labeled Comp Radiopharm 14:175–183CrossRef
7.
Zurück zum Zitat Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897–916PubMedCrossRef Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M (1977) The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897–916PubMedCrossRef
8.
Zurück zum Zitat Burton C, Ell P, Linch D (2004) The role of PET imaging in lymphoma. Br J Haematol 126:772–784PubMedCrossRef Burton C, Ell P, Linch D (2004) The role of PET imaging in lymphoma. Br J Haematol 126:772–784PubMedCrossRef
9.
Zurück zum Zitat Abbey CK, Borowsky AD, McGoldrick ET, Gregg JP, Maglione JE, Cardiff RD, Cherry SR (2004) In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci USA 101:11438–11443PubMedCrossRef Abbey CK, Borowsky AD, McGoldrick ET, Gregg JP, Maglione JE, Cardiff RD, Cherry SR (2004) In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia. Proc Natl Acad Sci USA 101:11438–11443PubMedCrossRef
10.
11.
Zurück zum Zitat Briones J, Timmerman J, Levy R (2002) In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res 62:3195–3199PubMed Briones J, Timmerman J, Levy R (2002) In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res 62:3195–3199PubMed
12.
Zurück zum Zitat Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O’Carroll K, Guarnieri F, Longo DL, Kwak LW (1996) Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 156:3858–3865PubMed Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O’Carroll K, Guarnieri F, Longo DL, Kwak LW (1996) Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 156:3858–3865PubMed
13.
Zurück zum Zitat Meziane el K, Bhattacharyya T, Armstrong AC, Qian C, Hawkins RE, Stern PL, Dermime S (2004) Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer 111:910–920PubMedCrossRef Meziane el K, Bhattacharyya T, Armstrong AC, Qian C, Hawkins RE, Stern PL, Dermime S (2004) Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer 111:910–920PubMedCrossRef
14.
Zurück zum Zitat Siegel S, Wagner A, Kabelitz D, Marget M, Coggin J Jr, Barsoum A, Rohrer J, Schmitz N, Zeis M (2003) Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 102:4416–4423PubMedCrossRef Siegel S, Wagner A, Kabelitz D, Marget M, Coggin J Jr, Barsoum A, Rohrer J, Schmitz N, Zeis M (2003) Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 102:4416–4423PubMedCrossRef
15.
Zurück zum Zitat Siegel S, Wagner A, Schmitz N, Zeis M (2003) Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 122:911–914PubMedCrossRef Siegel S, Wagner A, Schmitz N, Zeis M (2003) Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol 122:911–914PubMedCrossRef
16.
Zurück zum Zitat Zibert A, Balzer S, Souquet M, Quang TH, Paris-Scholz C, Roskrow M, Dilloo D (2004) CCL3/MIP-1alpha is a potent immunostimulator when coexpressed with interleukin-2 or granulocyte-macrophage colony-stimulating factor in a leukemia/lymphoma vaccine. Hum Gene Ther 15:21–34PubMedCrossRef Zibert A, Balzer S, Souquet M, Quang TH, Paris-Scholz C, Roskrow M, Dilloo D (2004) CCL3/MIP-1alpha is a potent immunostimulator when coexpressed with interleukin-2 or granulocyte-macrophage colony-stimulating factor in a leukemia/lymphoma vaccine. Hum Gene Ther 15:21–34PubMedCrossRef
17.
Zurück zum Zitat Rieger R, Kipps TJ (2003) CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res 63:4128–4135PubMed Rieger R, Kipps TJ (2003) CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Cancer Res 63:4128–4135PubMed
18.
Zurück zum Zitat Curti A, Parenza M, Colombo MP (2003) Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. Blood 101:568–575PubMedCrossRef Curti A, Parenza M, Colombo MP (2003) Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma. Blood 101:568–575PubMedCrossRef
19.
Zurück zum Zitat Passineau MJ, Siegal GP, Everts M, Pereboev A, Jhala D, Wang M, Zhu ZB, Park SK, Curiel DT, Nelson GM (2005) The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma. Leuk Lymphoma 46:1627–1638PubMedCrossRef Passineau MJ, Siegal GP, Everts M, Pereboev A, Jhala D, Wang M, Zhu ZB, Park SK, Curiel DT, Nelson GM (2005) The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma. Leuk Lymphoma 46:1627–1638PubMedCrossRef
20.
Zurück zum Zitat Molinier-Frenkel V, Lengagne R, Gaden F, Hong SS, Choppin J, Gahery-Segard H, Boulanger P, Guillet JG (2002) Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 76:127–135PubMedCrossRef Molinier-Frenkel V, Lengagne R, Gaden F, Hong SS, Choppin J, Gahery-Segard H, Boulanger P, Guillet JG (2002) Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 76:127–135PubMedCrossRef
21.
Zurück zum Zitat Graham MM, Peterson LM, Hayward RM (2000) Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 27:647–655PubMedCrossRef Graham MM, Peterson LM, Hayward RM (2000) Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 27:647–655PubMedCrossRef
22.
Zurück zum Zitat Lee JR, Madsen MT, Bushnel D, Menda Y (2000) A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun 21:685–690PubMedCrossRef Lee JR, Madsen MT, Bushnel D, Menda Y (2000) A threshold method to improve standardized uptake value reproducibility. Nucl Med Commun 21:685–690PubMedCrossRef
23.
Zurück zum Zitat Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R (1979) Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 122:549–554PubMed Kim KJ, Kanellopoulos-Langevin C, Merwin RM, Sachs DH, Asofsky R (1979) Establishment and characterization of BALB/c lymphoma lines with B cell properties. J Immunol 122:549–554PubMed
24.
Zurück zum Zitat Lotze MT, Papamichail M (2004) A primer on cancer immunology and immunotherapy. Cancer Immunol Immunother 53:135–138PubMedCrossRef Lotze MT, Papamichail M (2004) A primer on cancer immunology and immunotherapy. Cancer Immunol Immunother 53:135–138PubMedCrossRef
25.
Zurück zum Zitat Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH (2003) Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 198:1023–1034PubMedCrossRef Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH (2003) Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 198:1023–1034PubMedCrossRef
26.
Zurück zum Zitat Hoffman EJ, Huang SC, Phelps ME (1979) Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 3:299–308PubMedCrossRef Hoffman EJ, Huang SC, Phelps ME (1979) Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 3:299–308PubMedCrossRef
27.
Zurück zum Zitat Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, Fischer D (2005) PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med 46:758–762PubMed Israel O, Yefremov N, Bar-Shalom R, Kagana O, Frenkel A, Keidar Z, Fischer D (2005) PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med 46:758–762PubMed
28.
Zurück zum Zitat Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, Mortelmans L, Vandenberghe P, De Wolf-Peeters C (2003) [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 30:682–688PubMedCrossRef Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, Mortelmans L, Vandenberghe P, De Wolf-Peeters C (2003) [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 30:682–688PubMedCrossRef
29.
Zurück zum Zitat Yamada K, Brink I, Bisse E, Epting T, Engelhardt R (2005) Factors influencing [F-18] 2-fluoro-2-deoxy-d-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity. J Dermatol 32:316–334PubMed Yamada K, Brink I, Bisse E, Epting T, Engelhardt R (2005) Factors influencing [F-18] 2-fluoro-2-deoxy-d-glucose (F-18 FDG) uptake in melanoma cells: the role of proliferation rate, viability, glucose transporter expression and hexokinase activity. J Dermatol 32:316–334PubMed
30.
Zurück zum Zitat Uhr JW, Marches R (2001) Dormancy in a model of murine B cell lymphoma. Semin Cancer Biol 11:277–283PubMedCrossRef Uhr JW, Marches R (2001) Dormancy in a model of murine B cell lymphoma. Semin Cancer Biol 11:277–283PubMedCrossRef
31.
Zurück zum Zitat Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419PubMed Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419PubMed
32.
Zurück zum Zitat Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, Moser E, Glatting G, Kotzerke J, Guhlmann CA, Schirrmeister H, Reske SN (2001) 2-(fluorine-18)fluoro-2-deoxy-d-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial Cancer 91:889–899PubMedCrossRef Buchmann I, Reinhardt M, Elsner K, Bunjes D, Altehoefer C, Finke J, Moser E, Glatting G, Kotzerke J, Guhlmann CA, Schirrmeister H, Reske SN (2001) 2-(fluorine-18)fluoro-2-deoxy-d-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial Cancer 91:889–899PubMedCrossRef
33.
Zurück zum Zitat Bankert RB, Egilmez NK, Hess SD (2001) Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 22:386–393PubMedCrossRef Bankert RB, Egilmez NK, Hess SD (2001) Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 22:386–393PubMedCrossRef
Metadaten
Titel
[F-18]-Fluoro-2-deoxy-d-glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model
verfasst von
Coralie Chaise
Emmanuel Itti
Yolande Petegnief
Evelyne Wirquin
Christiane Copie-Bergman
Jean-Pierre Farcet
Marie-Hélène Delfau-Larue
Michel Meignan
Jean-Noël Talbot
Valérie Molinier-Frenkel
Publikationsdatum
01.08.2007
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 8/2007
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0265-0

Weitere Artikel der Ausgabe 8/2007

Cancer Immunology, Immunotherapy 8/2007 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.